Login to Your Account

BMS NASH drug reduces liver fat in phase II trial

By Michael Fitzhugh
Staff Writer

Monday, April 24, 2017

AMSTERDAM – Bristol-Myers Squibb Co.'s lead NASH candidate, BMS-986036, significantly reduced liver fat vs. placebo, meeting the primary endpoint of a phase II trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription